OXiGENE releases preclinical results at 2014 AACR meeting
May 2014
by  |  Email the author


SOUTH SAN FRANCISCO, Calif.—OXiGENE, Inc. has announced results from a trio of preclinical studies from its ongoing research and development programs, one of which was OXi4503, a dual-action vascular disrupting agent. OXi4503 was administered to a preclinical model of breast cancer with a stereotactic radiation schedule plus mild temperature hyperthermia. The study showed OXi4503 potentiated the radiation’s effects and might have potential as a radiosensitizing agent. Another study investigated the anti-tumor activity and pharmacokinetics of KGP94, a small-molecule cathepsin L inhibitor, in models of breast and squamous cell head and neck cancer, demonstrating that the compound significantly delays tumor growth. The third study looked at the anti-metastatic and anti-bone resorptive activity of KGP94 in a preclinical model of prostate cancer and found that small-molecule cathepsin L targeting could significantly reduce metastatic dissemination of prostate cancer cells and impair bone resorption.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.